@prefix chebi: . @prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix schem: . @prefix obo: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 occursIn: obo:CL_0000233, species:9606; rdf:object schem:cyclic%20AMP; rdf:predicate belv:increases; rdf:subject chebi:15551; a rdf:Statement . sub:assertion rdfs:label "a(SCHEM:Dinoprostone) -> a(SCHEM:\"cyclic AMP\")" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_3; pav:version "20131211" . sub:_2 prov:value "3. On human washed platelet suspensions the PGE analogues, with the exception of butaprost,inhibited the rise in adenosine 3':5'-cyclic monophosphate (cyclic AMP) induced by cicaprost (8 nM).PGE2 produced a monophasic inhibition curve (IC50 = 5.4 nM, 92% inhibition at 600 nM). "; prov:wasQuotedFrom pubmed:8448586 . sub:_3 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:8448586; prov:wasDerivedFrom beldoc:, sub:_2 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:49.754+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }